ha14-1 has been researched along with Leukemia, T-Cell in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
Leukemia, T-Cell: A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, JH | 1 |
| Yu, M | 1 |
| Liu, FT | 1 |
| Newland, AC | 1 |
| Jia, L | 1 |
1 other study available for ha14-1 and Leukemia, T-Cell
| Article | Year |
|---|---|
Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Benzamides; Benzopyrans; Carbo | 2004 |